FATE
Fate Therapeutics, Inc.·Healthcare
1.24
2.362%(−0.03)
Market ClosedLast Updated: — ET
52W L: $0.8752W H: $1.94
FATE NEWS
globenewswire.com
Apr 2
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2026, the Company granted restricted stock units (RSUs) representing 7,260 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
prnewswire.com
Mar 27
Scalable Biotech Manufacturing Unlocks a $14B Market
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to
defenseworld.net
Mar 23
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of “Hold” from Brokerages
Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) has earned an average rating of "Hold" from the eight ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have given a buy recommendation to the company. The
globenewswire.com
Mar 4
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on March 2, 2026, the Company granted restricted stock units (RSUs) representing 50,700 shares of its common stock to three newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.
globenewswire.com
Mar 3
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat and host investor meetings at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.
prnewswire.com
Mar 3
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical
